Altimmune, Inc. — Director's Dealing 2010

Nov 5, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PHARMATHENE, INC (PIP)
CIK: 0001326190
Period of Report: 2010-11-03

Reporting Person: EVNIN LUKE (10% Owner)
Reporting Person: GALAKATOS NICHOLAS (10% Owner)
Reporting Person: HENNER DENNIS (10% Owner)
Reporting Person: STEINMETZ MICHAEL (10% Owner)
Reporting Person: GADICKE ANSBERT (10% Owner)
Reporting Person: WHEELER KURT (10% Owner)
Reporting Person: SIMON NICHOLAS J III (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-11-03	Common Stock	C	2428171	$2.5417	Acquired	5917614	Indirect
2010-11-03	Common Stock	P	430000	$3.50	Acquired	6347614	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-11-03	10% Convertible Note	$2.5417	C		Disposed	2011-07-28	Common Stock (2428171)	Indirect

Footnotes

F1: These notes were held in principal amount as follows: $304,967.95 by MPM BioVentures III, L.P. ("BV III"), $4,535,272.77 by MPM BioVentures III-QP, L.P. ("BV III QP"), $383,274.43 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG"), $136,981.07 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and $107,818.80 by MPM Asset Management Investors 2004 BVIII LLC ("AM 2004"). Amounts reflected above also include accrued interest on the notes as follows: $39,222.27 by BV III, $583,286.47 by BV III QP, $49,293.35 by BV KG, $17,617.29 by BV Parallel and $13,866.70 by AM 2004. MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III and BV Parallel and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the members of MPM III LLC and AM 2004. Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F2: Immediately convertible into shares of Common Stock of the Issuer at the rate of $2.541667 per share.

F3: The shares were acquired as follows: 135,419 by BV III, 2,013,859 by BV III QP, 170,191 by BV KG, 60,826 by BV Parallel and 47,876 by AM 2004.

F4: The shares are held as follows: 330,024 by BV III, 4,907,913 by BV III QP, 414,765 by BV KG, 148,235 by BV Parallel and 116,677 by AM 2004. Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

F5: The shares were purchased as follows: 23,981 by BV III, 356,630 by BV III QP, 30,139 by BV KG, 10,772 by BV Parallel and 8,478 by AM 2004.

F6: The shares are held as follows: 354,005 by BV III, 5,264,543 by BV III QP, 444,904 by BV KG, 159,007 by BV Parallel and 125,155 by AM 2004. Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.